Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Probability Laws

Probability Laws

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Myocardial infarction risk is increased by periodontal pathobionts: a cross-sectional study.

Scientific reports·2022

Same author

Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.

Current oncology (Toronto, Ont.)·2020

Same author

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.

Current oncology (Toronto, Ont.)·2019

Same author

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

European journal of cancer (Oxford, England : 1990)·2018

Same author

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Topotecan and cyclophosphamide in adults with relapsed sarcoma.

Sarcoma·2012

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.

K B Niendorf¹, W Goggins, G Yang

¹Center for Cancer Risk Analysis, Massachusetts General Hospital, Boston, MA 02114, USA.

Journal of Medical Genetics

|September 20, 2005

Summary

This summary is machine-generated.

This study developed MELPREDICT, a model to estimate the probability of carrying CDKN2A mutations in familial melanoma patients. The model shows robust performance in identifying mutation carriers, aiding in risk assessment for hereditary melanoma.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Related Experiment Videos

Last Updated: Jul 12, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Area of Science:

Genetics
Oncology
Medical Informatics

Background:

Germline alterations in the CDKN2A gene are associated with a portion of familial melanoma cases.
A reliable method for identifying individuals at risk of being CDKN2A mutation carriers is currently lacking.

Purpose of the Study:

To develop and validate a predictive model for estimating CDKN2A mutation carrier probability in familial cutaneous melanoma.
To identify clinical features associated with CDKN2A germline mutations.

Main Methods:

A logistic regression model (MELPREDICT) was constructed using data from 116 familial cutaneous melanoma patients.
Clinical features including proband age at diagnosis, number of proband primaries, and number of additional family primaries were analyzed.
The model's performance was evaluated using an external validation cohort.

Main Results:

The MELPREDICT model incorporates age, proband primaries, and family primaries to estimate carrier probability.
The model achieved an area under the curve of 0.881 in the Boston dataset and 0.803 in an external Toronto cohort.
Mean estimated probabilities were 55.4% for carriers and 5.1% for non-carriers in the Boston cohort.

Conclusions:

The developed logistic regression model (MELPREDICT) provides a first-iteration approximation of CDKN2A carrier probability.
External validation demonstrated relatively robust performance of the MELPREDICT model.
This model can aid in identifying individuals at higher risk for CDKN2A mutations in familial melanoma.